DexCom Q3 2024 Adj EPS $0.45 Beats $0.43 Estimate, Sales $994.20M Beat $990.71M Estimate
Portfolio Pulse from Benzinga Newsdesk
DexCom reported Q3 2024 earnings per share of $0.45, surpassing the analyst estimate of $0.43. The company's sales reached $994.20 million, exceeding the expected $990.71 million and marking a 1.97% increase from the previous year.
October 24, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DexCom's Q3 2024 earnings and sales exceeded analyst expectations, with EPS at $0.45 and sales at $994.20M, indicating positive financial performance.
DexCom's earnings per share and sales both exceeded analyst expectations, which is typically a positive indicator for stock performance. The beat on both EPS and sales suggests strong operational performance and could lead to a positive market reaction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100